Report on diagnosis and treatment of hemophilia in China 2023

doi:10.16150/j.1671-2870.2023.02.001

Abstract

Abstract:

In recent years, China attaches great importance to the prevention and treatment of rare diseases. As one of the representative diseases of rare diseases, management of Hemophilia has made great progress in China. From 1986 to 1989, the National Hemophilia Cooperative Group conducted China's hemophilia epidemiological survey according to the unified method and standard, and the results showed that the prevalence of hemophilia was 2.73/100 000, and there was no statistical difference in prevalence among different regions. In 2014, Meta-analysis showed that the prevalence of hemophilia in China was 2.8/100 000, and in 2018, based on the data of the urban population of Tianjin, the local prevalence of hemophilia was estimated to be 3.09/100 000. With the comprehensive promotion of the construction of hemophilia hierarchical diagnosis and treatment system, China requires that hospitals applying for hemophilia comprehensive management centers and diagnosis and treatment centers must be able to independently carry out screening tests and confirmatory tests related to hemophilia diagnosis. For diagnosis of hemophilia, most laboratories in China usually adopt the one-stage method (coagulation method) based on the activated partial thromboplastin time (APTT) for the determination of coagulation factor activity, but it should be noted that more than two activity detection methods are required for some special types of hemophilia. The types of each mutation in the F8 gene of patients in China are similar to those reported in international data, and the mutations in the F9 gene of our patients are mainly single base point mutations, with no mutation hotspots found. As of June 2023, a total of more than 40 000 cases with inherited bleeding disorders registered in 261 centers in China (including hemophilia), through the National Hemophilia Registration System. The history of hemophilia treatment in China has been explored through inadequate on-demand and low-dose prophylaxis, and is now moving towards higher-dose prophylaxis and individualized prophylaxis with higher efficacy. Based on the above registry data and literature, this report comprehensively summarizes the progress of basic and clinical research and medical protection in the field of hemophilia in China, and analyzes the shortcomings for further improvement of hemophilia diagnosis and treatment in China.

Key words: Hemophilia, Prevalence, Hereditary hemorrhagic disease, Joint deformity, Coagulant factor inhibitor

CLC Number:

R554.1

XUE Feng, DAI Jing, CHEN Lixia, LIU Wei, ZHANG Houqiang, WU Runhui, SUN Jing, ZHANG Xinsheng, WU Jingsheng, ZHAO Yongqiang, WANG Xuefeng, YANG Renchi. Report on diagnosis and treatment of hemophilia in China 2023[J]. Journal of Diagnostics Concepts & Practice, 2023, 22(02): 89-115.

Figures/Tables 3

References 139

[1]	薛峰, 杨仁池. 国家血友病登记系统建设[J]. 罕见病研究, 2022, 1(4):370-374.
	XUE F, YANG R C. Establishment and Evolution of China National Hemophilia Registry[J]. J Rare Dis, 2022, 1(4):370-374.
[2]	曲艳吉, 聂晓璐, 杨智荣, 等. 中国大陆血友病患病率的Meta分析[J]. 中华血液学杂志, 2014, 35(1):65-68.
	QU Y J, NIE XL, YANG ZR, et al. Meta analysis of the prevalence of hemophilia in mainland China[J]. Chin J Hematol, 2014, 35(1):65-68.
[3]	SONG X, LIU W, XUE F, et al. Real-world analysis of haemophilia patients in China: A single centre's experie-nce[J]. Haemophilia, 2020, 26(4):584-590. doi: 10.1111/hae.v26.4 URL
[4]	SONG X, ZHONG J, XUE F, et al. An overview of patients with haemophilia A in China: Epidemiology, disease severity and treatment strategies[J]. Haemophilia, 2021, 27(1):e51-e59. doi: 10.1111/hae.14217 pmid: 33245829
[5]	ZHANG W, SONG X, DOU X, et al. Demographics, clinical profile and treatment landscape of patients with haemophilia B in China[J]. Haemophilia, 2022, 28(2):e56-e60. doi: 10.1111/hae.14484 pmid: 34985173
[6]	ZHANG W, LI K, POON M C, et al. Women and girls with haemophilia: A retrospective cohort study in China[J]. Haemophilia, 2023, 29(2):578-590. doi: 10.1111/hae.14740 pmid: 36595620
[7]	中国血友病协作组. 血友病中心建设标准探讨[J]. 临床血液学杂志, 2019, 32(3):182-185.
	Hemophilia Treatment Center Collaborative Network of China. Tentative standard for the establishment of hemophilia center[J]. J Clin Hematol, 2019, 32(3):182-185.
[8]	中华人民共和国国家卫生健康委员会. 凝血因子活性测定技术标准[S/OL]. WS/T 220-2021. http://www.nhc.gov.cn/fzs/s7852d/202109/c8ea94e5f7a54e609755a4fe48e0f95e/files/7546fe06108e4bf4a72a54c336c50daf.pdf.
[9]	刘禹, 许冠群, 王学锋, 等. 发色底物法检测凝血因子Ⅷ活性的临床应用评价[J]. 中华检验医学杂志, 2020, 43(8):816-822.
	LIU Y, XU G Q, WANG X F, et al. Clinical application evaluation of chromogenic substrate assay in detecting coa-gulation factor Ⅷ activity[J]. Chin J Lab Med, 2020, 43(8):816-822.
[10]	HUANG L, LI L, LI Q, et al. Different clinical phenotypes caused by three F8 missense mutations in three chinese families with moderate hemophilia A[J]. DNA Cell Biol, 2020, 39(9):1685-1690. doi: 10.1089/dna.2020.5359 URL
[11]	中国研究型医院学会血栓与止血专委会. 活化部分凝血活酶时间延长混合血浆纠正试验操作流程及结果解读中国专家共识[J]. 中华检验医学杂志, 2021, 44(8):690-697.
	Chinese Society on Thrombosis and Hemostasis. Chinese expert consensus on operation procedure and result interpretation of APTT mixing test[J]. Chin J Lab Med, 2021, 44(8):690-697.
[12]	刘禹, 许冠群, 戴菁, 等. 凝血因子Ⅷ活性检测现状及发展趋势[J]. 中华检验医学杂志, 2022, 45(10):1010-1016.
	LIU Y, XU G Q, DAI J, et al. Current status and development trend of coagulation factor Ⅷ activity[J]. Chin J Lab Med, 2022, 45(10):1010-1016.
[13]	LAKICH D, KAZAZIAN H H Jr, ANTONARAKIS S E, et al. Inversions disrupting the factor Ⅷ gene are a common cause of severe haemophilia A[J]. Nat Genet, 1993, 5(3):236-241. doi: 10.1038/ng1193-236
[14]	BAGNALL R D, WASEEM N, GREEN P M, et al. Recurrent inversion breaking intron 1 of the factor Ⅷ gene is a frequent cause of severe hemophilia A[J]. Blood, 2002, 99(1):168-174. doi: 10.1182/blood.V99.1.168 URL
[15]	MCVEY J H, RALLAPALLI P M, KEMBALL-COOK G, et al. The European Association for Haemophilia and Allied Disorders (EAHAD) Coagulation Factor Variant Databases: Important resources for haemostasis clinicians and researchers[J]. Haemophilia, 2020, 26(2):306-313. doi: 10.1111/hae.13947 pmid: 32166871
[16]	LU Y, XIN Y, DAI J, et al. Spectrum and origin of mutations in sporadic cases of haemophilia A in China[J]. Haemophilia, 2018, 24(2):291-298. doi: 10.1111/hae.13402 pmid: 29381227
[17]	LU Y, WU X, DAI J, et al. The characteristics and spectrum of F9 mutations in Chinese sporadic haemophilia B pedigrees[J]. Haemophilia, 2019, 25(2):316-323. doi: 10.1111/hae.2019.25.issue-2 URL
[18]	HUANG L, LI L, LIN S, et al. Molecular analysis of 76 Chinese hemophilia B pedigrees and the identification of 10 novel mutations[J]. Mol Genet Genomic Med, 2020, 8(11):e1482.
[19]	ZHANG X, WANG G, CHEN K, et al. Identification of five novel variants of haemophilia B in 32 patients in Shanxi province, China[J]. Haemophilia, 2020, 26(4):e217-e219.
[20]	LU L, ZHANG X, REN J, et al. Comprehensive analysis of genotypes and phenotypes in 23 Chinese patients with hemophilia B: Identification of five novel variants[J]. Int J Lab Hematol, 2023, 45(3):e71-e74.
[21]	DING Q L, LU Y L, DAI J, et al. Characterisation and validation of a novel panel of the six short tandem repeats for genetic counselling in Chinese haemophilia A pedigrees[J]. Haemophilia, 2012, 18(4):621-625. doi: 10.1111/j.1365-2516.2011.02732.x pmid: 22276966
[22]	CHEN C, XIE X, WU X, et al. Complex recombination with deletion in the F8 and duplication in the TMLHE mediated by int22h copies during early embryogenesis[J]. Thromb Haemost, 2017, 117(8):1478-1485. doi: 10.1160/TH17-01-0046 URL
[23]	YOU G L, DING Q L, LU Y L, et al. Characterization of large deletions in the F8 gene using multiple competitive amplification and the genome walking technique[J]. J Thromb Haemost, 2013, 11(6):1103-1110. doi: 10.1111/jth.12205 URL
[24]	LYU C, XUE F, LIU X, et al. Identification of mutations in the F8 and F9 gene in families with haemophilia using targeted high-throughput sequencing[J]. Haemophilia, 2016, 22(5):e427-e434. doi: 10.1111/hae.2016.22.issue-5 URL
[25]	LI Q, CHEN J, LIN S, et al. Target capture next-generation sequencing in non-inversion haemophilia: an alternative approach[J]. Br J Haematol, 2020, 189(4):e168-e170.
[26]	CHEN J, LI Q, LIN S, et al. The spectrum of FⅧ gene variants detected by next generation sequencing in 236 Chinese non-inversion hemophilia A pedigrees[J]. Thromb Res, 2021, 202:8-13. doi: 10.1016/j.thromres.2021.02.027 URL
[27]	ZHANG W, LI K, POON M C, et al. Women and girls with haemophilia: A retrospective cohort study in China[J]. Haemophilia, 2023, 29(2):578-590. doi: 10.1111/hae.14740 pmid: 36595620
[28]	中华医学会血液学分会血栓与止血学组, 中国血友病协作组. 血友病治疗中国指南(2020年版)[J]. 中华血液学杂志, 2020, 41(4):265-271.
	Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association/Hemophilia Treatment Center Collaborative Network of China. Chinese guidelines on the treatment of hemophilia (version 2020)[J]. Chin J Hematol, 2020, 41(4):265-271.
[29]	SRIVASTAVA A, SANTAGOSTINO E, DOUGALL A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition[J]. Haemophilia, 2020, 26(Suppl 6):1-158. doi: 10.1111/hae.v26.s2 URL
[30]	WU R, LUKE K H, POON M C, et al. Low dose secon-dary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China[J]. Haemophilia, 2011, 17(1):70-74. doi: 10.1111/hae.2010.17.issue-1 URL
[31]	TANG L, WU R, SUN J, et al. Short-term low-dose secon-dary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China[J]. Haemophilia, 2013, 19(1):27-34. doi: 10.1111/hae.2012.19.issue-1 URL
[32]	YAO W, XIAO J, CHENG X, et al. The efficacy of recombinant FⅧ low-dose prophylaxis in chinese pediatric patients with severe hemophilia A: a retrospective analysis from the ReCARE study[J]. Clin Appl Thromb Hemost, 2017, 23(7):851-858. doi: 10.1177/1076029616679507 URL
[33]	LIU Y, CHEN L, LI K, et al. Severe haemophilia A children on low-dose tertiary prophylaxis showed less joint deterioration and better maintenance of functional independence than children on on-demand treatment: A 6-year follow-up study[J]. Haemophilia, 2020, 26(5):779-785. doi: 10.1111/hae.v26.5 URL
[34]	庄金木, 孙雪岩, 周璇, 等. 低中剂量凝血因子Ⅷ预防治疗重型血友病A患儿:关节综合评估及相关性分析[J]. 南方医科大学学报, 2018, 38(4):496-501.
	ZHUANG J M, SUN X Y, ZHOU X, et al. Prophylactic treatment with low- and intermediate-dose factor Ⅷ in children with severe hemophilia A: comprehensive evaluation of joint outcomes and correlation analysis[J]. J South Med Univ, 2018, 38(4):496-501.
[35]	HUA B, LEE A, FAN L, et al. Low-dose factor Ⅷ infusion in Chinese adult haemophilia A patients: pharmacokinetics evidence that daily infusion results in higher trough level than with every-other-day infusion with similar factor Ⅷ consumption[J]. Haemophilia, 2017, 23(3):417-421. doi: 10.1111/hae.2017.23.issue-3 URL
[36]	LIU S, ZHANG P Y, JIN Z B, et al. What can we expect for adolescents and adults with haemophilia switched to low-dose prophylaxis from episodic treatment for over 3 years? A real-world snapshot in China[J]. Haemophilia, 2021, 27(5):e624-e627. doi: 10.1111/hae.14361 pmid: 34118092
[37]	ZHAO Y, HU Y, JIN J, et al. Phase 4 safety and efficacy study of antihemophilic factor (Recombinant) in previou-sly treated Chinese patients with severe/moderately severe hemophilia A[J]. Clin Appl Thromb Hemost, 2021, 27:1076029621989811.
[38]	周荣富, 李倩, 欧阳建, 等. 第三代全长链重组凝血因子Ⅷ预防治疗中间型重型血友病A患儿疗效和安全性评估[J]. 中国实用儿科杂志, 2017, 32(1):59-62.
	ZHOU R F, LI Q, OUYANG J, et al. Efficacy and safety of third-generation full length recombinant human coagulation factor Ⅷ in the prophylactic treatment of childhood patients with moderate-to-severe hemophilia A: A single center experience[J]. Chin J Pract Pediatr, 2017, 32(1):59-62.
[39]	孙雪岩, 庄金木, 周璇, 等. 中国重型血友病A成人患者短期足量预防治疗的疗效[J]. 南方医科大学学报, 2018, 38(10):1222-1227.
	SUN X Y, ZHUANG J M, ZHOU X, et al. Efficacy of short-term full-dose prophylaxis in adult Chinese patients with severe hemophilia A[J]. J South Med Univ, 2018, 38(10):1222-1227.
[40]	CHEN Z P, LI P J, LI G, et al. Pharmacokinetic studies of factor Ⅷ in Chinese boys with severe hemophilia A: A single-center study[J]. Chin Med J (Engl), 2018, 131(15):1780-1785.
[41]	WU R, LI X, YAO W, et al. Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low-dose secondary prophylaxis study[J]. Res Pract Thromb Haemost, 2021, 5(6):e12552. doi: 10.1002/rth2.12552 URL
[42]	LI P, CHEN Z, CHENG X, et al. PK-tailored tertiary prophylaxis in patients with severe hemophilia A at Beijing Children's Hospital[J]. Pediatr Investig, 2019, 3(1):45-49. doi: 10.1002/ped4.2019.3.issue-1 URL
[43]	HUANG K, ZHEN Y, LI G, et al. Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half-life factor Ⅷ concentrates[J]. Res Pract Thromb Haemost, 2022, 6(2):e12686. doi: 10.1002/rth2.12686 URL
[44]	HUANG K, AI D, LI G, et al. Individualised prophylaxis based on personalised target trough FⅧ level optimised clinical outcomes in paediatric patients with severe haemophilia A[J]. Haemophilia, 2022, 28(6):e209-e218.
[45]	中国血友病协作组. 药物代谢动力学指导血友病A治疗的中国专家共识[J]. 中国临床研究, 2021, 34(5):577-581,591.
	Hemophilia Treatment Center Collaborative Network of China. Chinese expert consensus on pharmacokinetics guided treatment for hemophilia A[J]. Chin J Clin Res, 2021, 34(5):577-581,591.
[46]	蔡力生, 帕拉赛提·阿地力, 杜新, 等. 评价蔡氏公式用于接受Turoctocog alfa治疗的中国重型血友病A经治患者的准确性[J]. 血栓与止血学, 2022, 28(6):1214-1220.
	CAI L S, PALASAITI A, DU X, et al. Evaluation of Cai's formula in Chinese previously treated patients with severe hemophilia a receiving Turoctocog alfa[J]. Chin J Thromb Hemost, 2022, 28(6):1214-1220.
[47]	XUE F, ZHAO X, SUN J, et al. Pharmacokinetic, efficacy and safety evaluation of B-domain-deleted recombinant FⅧ (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A[J]. Haemophilia, 2021, 27(5):814-822. doi: 10.1111/hae.v27.5 URL
[48]	WU R, WANG X, ZHAO X, et al. Efficacy, safety and pharmacokinetics of recombinant human coagulation factor Ⅷ (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A[J]. Haemophilia, 2022, 28(6):e199-e208.
[49]	WU R, SUN J, XU W, et al. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeding episodes in previously treated patients from China with severe hemophilia A: results from the Guardian 7 Trial[J]. Ther Clin Risk Manag, 2020, 16:567-578. doi: 10.2147/TCRM.S243146 URL
[50]	XI Y, JIN C, LIU W, et al. Efficacy, safety and bioequivalence of the human-derived B-domain-deleted recombinant factor Ⅷ TQG202 for prophylaxis in severe haemophilia A patients[J]. Haemophilia, 2022, 28(6):e219-e227.
[51]	SUN Z, XI Y, LIU W, et al. Efficacy and safety of the B-domain-deleted TQG202 for on-demand treatment in moderate and severe haemophilia A patients: A multicentre, single-arm trial[J]. Haemophilia, 2023, 29(4):997-1004. doi: 10.1111/hae.v29.4 URL
[52]	YANG R, WANG S, WANG X, et al. Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5)[J]. Res Pract Thromb Haemost, 2022, 6(2):e12670. doi: 10.1002/rth2.12670 URL
[53]	LIU G, HUANG K, LI G, et al. Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China[J]. Front Pediatr, 2022, 10:992267. doi: 10.3389/fped.2022.992267 URL
[54]	XUE F, LI H, WU X, et al. Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor Ⅸ administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial[J]. Lancet Haematol, 2022, 9(7):e504-e513. doi: 10.1016/S2352-3026(22)00113-2 URL
[55]	XUE F, WANG P, YUAN Z, et al. Total knee arthroplasty after gene therapy for hemophilia B[J]. N Engl J Med, 2022, 387(17):1622-1624. doi: 10.1056/NEJMc2211173 URL
[56]	童培建, 翁习生, 杨仁池, 等. 中国血友病性骨关节病髋膝关节置换围手术期管理指南[J]. 中华骨与关节外科杂志, 2022, 15(7):481-490.
	TONG P J, WENG X S, YANG R C, et al. Guideline for perioperative management in hemophilic arthropathy patients undergoing hip and/or knee arthroplasty in China[J]. Chin J Bone Joint Surg, 2022, 15(7):481-490.
[57]	中华医学会骨科学分会关节外科学组,中国血友病协作组. 中国血友病骨科手术围手术期管理指南[J]. 中华骨科杂志, 2023, 43(4):215-222.
	The Joint Surgery Branch of the Chinese Orthopaedic Association, Hemophilia Treatment Center Collaborative Network of China. Guideline for perioperative management of hemophilia patients undergoing orthopaedic surgery in China[J]. Chin J Orthop, 2023, 43(4):215-222.
[58]	WU G L, ZHAI J L, FENG B, et al. Total hip arthroplasty in hemophilia patients: A mid-term to long-term follow-up[J]. Orthop Surg, 2017, 9(4):359-364. doi: 10.1111/os.2017.9.issue-4 URL
[59]	HUANG Z Y, HUANG Q, ZENG H J, et al. Tranexamic acid may benefit patients undergoing total hip/knee arthroplasty because of haemophilia[J]. BMC Musculoske-let Disord, 2019, 20(1):402.
[60]	FENG B, XIAO K, GAO P, et al. Comparison of 90-day complication rates and cost between single and multiple joint procedures for end-stage arthropathy in patients with hemophilia[J]. JB JS Open Access, 2018, 3(4):e0026.
[61]	JIANG C, ZHAO Y, FENG B, et al. Simultaneous bila-teral total knee arthroplasty in patients with end-stage hemophilic arthropathy: a mean follow-up of 6 years[J]. Sci Rep, 2018, 8(1):1608. doi: 10.1038/s41598-018-19852-7
[62]	LI Z, FENG B, DU Y, et al. Complications of total knee arthroplasty in patients with haemophilia compared with osteoarthritis and rheumatoid arthritis: A 20-year single-surgeon cohort[J]. Haemophilia, 2020, 26(5):861-866. doi: 10.1111/hae.v26.5 URL
[63]	冯宾, 朱威, 高鹏, 等. 血友病性骨骼肌肉病变的外科治疗[J]. 中华血液学杂志, 2020. 41(11):903-907.
	FENG B, ZHU W, GAO P, et al. Orthopedic treatment of musculoskeletal disorders in hemophilic patients[J]. Zhonghua Xue Ye Xue Za Zhi, 2020, 41(11):903-907.
[64]	SHEN S N, WU D X, LV S J, et al. Hidden blood loss of total knee arthroplasty in hemophilia arthritis: an analysis of influencing factors[J]. BMC Musculoskelet Disord, 2022, 23(1):587. doi: 10.1186/s12891-022-05535-y
[65]	LI Z, XIAO K, CHANG X, et al. A novel surgical classification for extremity and pelvic hemophilic pseudotumors: the PUMCH classification[J]. J Bone Joint Surg Am, 2023, 105(8):630-637. doi: 10.2106/JBJS.22.00781 URL
[66]	范猛, 马乐, 姜文学. 血友病性假肿瘤的外科治疗[J]. 中国矫形外科杂志, 2020, 28(1):85-87.
	FAN M, MA L, JIANG W X. Surgical treatment of haemophilia pseudotumor[J]. Orthop J China, 2020, 28(1):85-87.
[67]	LIN S, TONG K, WANG G, et al. Clinical characteristics and surgical treatment of haemophilic pseudotumor: A retrospective analysis of thirty-four patients[J]. Haemophilia, 2020, 26(5):873-881. doi: 10.1111/hae.v26.5 URL
[68]	ZHAI J, WENG X, ZHANG B, et al. Surgical treatment for hemophilic pseudotumor: twenty-three cases with an average follow-up of 5 years[J]. J Bone Joint Surg Am, 2017, 99(11):947-953. doi: 10.2106/JBJS.16.01299 pmid: 28590380
[69]	XU Y, FENG B, ZHU W, et al. Risk factors for amputation in the surgical treatment of hemophilic osteoarthropathy: a 20-year single-center report[J]. Pain Res Manag, 2022, 2022:1512616.
[70]	ZHANG T, HUANG S, XU S, et al. Clinical outcomes of arthroscopic synovectomy for adolescent or young adult patients with advanced haemophilic arthropathy[J]. Exp Ther Med, 2018, 16(5):3883-3888. doi: 10.3892/etm.2018.6709 pmid: 30344665
[71]	孙利, 姜文学, 范猛, 等. ³²P胶体放射性滑膜切除术治疗血友病性滑膜炎的效果[J]. 广东医学, 2019, 40(5):715-719,723.
	SUN L, JIANG W X, FAN M, et al. Effect of radioactive synovectomy with ³²P colloid on haemophilia synovitis[J]. Guangdong Med J, 2019, 40(5):715-719,723.
[72]	FENG B, LI Z, FENG C, et al. Early wound complications after orthopaedic surgery for haemophilia: What can we do more[J]. Haemophilia, 2020, 26(5):882-890. doi: 10.1111/hae.v26.5 URL
[73]	SUN J, HILLIARD P E, FELDMAN B M, et al. Chinese Hemophilia Joint Health Score 2.1 reliability study[J]. Haemophilia, 2014, 20(3):435-440. doi: 10.1111/hae.12330 pmid: 24330460
[74]	张厚强, 刘淑芬, 史明楠, 等. 血友病儿童膝关节挛缩康复治疗效果的最小临床重要差异[J]. 中华物理医学与康复杂志, 2022, 44(12):1095-1099.
	ZHANG H Q, LIU S F, SHI M N, et al. The minimum clinically-important difference in rehabilitation for children with haemophilic knee joint contracture[J]. Chin J Phys Med Rehabil, 2022, 44(12):1095-1099.
[75]	王岩, 艾迪, 李晓静, 等. 血友病关节健康评分在学龄前儿童血友病关节评价中的应用——一项多中心儿童重型血友病A临床数据分析[J]. 中国实用儿科杂志, 2020, 35(2):116-119.
	WANG Y, AI D, LI X J, et al. Role of hemophilia joint health score (HJHS) in the evaluation of hemophilia joints in preschool children: A clinical data analysis of a multicenter children with severe hemophilia A[J]. Chin J Pract Pediatr, 2020, 35(2):116-119.
[76]	中国血友病协作组, 中国罕见病联盟血友病学组. 中国血友病骨骼肌肉并发症康复评估与治疗专家共识[J]. 罕见病研究, 2022, 1(4):420-427.
	Hemophilia Treatment Center Collaborative Network of China, China Alliance for Rare Diseases, Hemophilia Subcommittee. Expert consensus on assessment for rehabilitation and treatment of musculoskeletal complications of hemophilia in China[J]. J Rare Dis, 2022, 1(4):420-427.
[77]	杨仁池. 中国血友病管理指南2021[M]. 中国协和医科大学出版社, 2021.
[78]	OUYANG J, ZHANG B, KUANG L, et al. Pulsed electromagnetic field inhibits synovitis via enhancing the efferocytosis of macrophages[J]. Biomed Res Int, 2020, 2020:4307385.
[79]	陈晓顶, 黄瑛, 吴旭才, 等. 脉冲短波治疗血友病伴膝关节出血患者的疗效观察[J]. 中华物理医学与康复杂志, 2016, 38(7):543-544.
	CHEN X D, HUANG Y, WU X C, et al. Therapeutic effect of pulsed short wave therapy on Haemophilia patients with knee joint hemorrhage[J]. Chin J Phys Med Rehabil, 2016, 38(7):543-544.
[80]	曾艳, 韩红, 陈慧, 等. 凝血因子输注联合激光照射对血友病患者急性皮肤、肌肉及关节出血的疗效[J]. 武汉大学学报(医学版), 2019, 40(3):492-495.
	ZENG Y, HAN H, CHEN H, et al. Clinical effect of laser irradiation combined with coagulation factor on acute skin muscle and joint hemorrhage in patients with hemophilia[J]. Med J Wuhan Univ, 2019, 40(3):492-495.
[81]	LO W S, SHEEN J M, CHEN Y C, et al. The application of focused medium-energy extracorporeal shockwave therapy in hemophilic a arthropathy[J]. Healthcare (Basel), 2022, 10(2):352.
[82]	杜威, 李要春, 唐银波, 等. 血友病性慢性疼痛的综合康复治疗[J]. 中国现代医学杂志, 2019, 29(7):117-120.
	DU W, LI Y C, TANG Y B, et al. Comprehensive rehabilitation therapy of hemophilic chronic pain[J]. China J Modern Med, 2019, 29(7):117-120.
[83]	李要春, 唐银波, 冷屹, 等. 高强度训练在血友病性膝关节炎患者康复治疗中的应用[J]. 中国医学工程, 2021, 29(6):38-41.
	LI Y C, TANG Y B, LENG Y, et al. Application of high-intensity training in rehabilitation treatment of haemophilic knee arthropathy[J]. China Med Eng, 2021, 29(6):38-41.
[84]	刘颖, 史明楠, 赵沃娃, 等. 血友病康复从业人员工作及培训现状分析[J]. 中华医学教育杂志, 2021, 41(4): 297-300.
	LIU Y, SHI M N, ZHAO W W, et al. Analysis of current situation of work and training of hemophilia rehabilitation practitioners[J]. Chin J Med Ed, 2021, 41(4):297-300.
[85]	陈丽霞, 吴润辉, 张光宇, 等. 本体感觉训练对儿童血友病患者下肢靶关节出血频率的影响[J]. 中国康复医学杂志, 2010, 25(4):340-342.
	CHEN L X, WU R H, ZHANG G Y, et al. Affects of proprioception training on bleeding frequency in target joints of low extremities in children with moderate-severe hemophilia[J]. Chin J Rehabil Med, 2010, 25(4):340-342.
[86]	贾莉, 梁小慧, 黄莉. 家庭康复训练对成年早期血友病性膝关节炎患者膝关节功能的影响及其防跌倒效果分析[J]. 中国医学前沿杂志(电子版), 2021, 13(8):15-19.
	JIA L, LIANG X H, HUANG L. Analysis of the effect of family rehabilitation training on knee joint function and anti-fall effect in adult patients with early hemophilic knee arthritis[J]. Chin J Front Med Sci(El Version), 2021, 13(8):15-19.
[87]	郭玉林, 赵华, 田丽姣, 等. 家庭康复训练在血友病病人家庭护理中的应用[J]. 护理研究, 2019, 33(17):3074-3077.
	GUO Y L, ZHAO H, TIAN L J, et al. Application of fa-mily rehabilitation training in family nursing of patients with hemophilia[J]. Chin Nurs Res, 2019, 33(17):3074-3077.
[88]	KEHLET H. Multimodal approach to control postoperative pathophysiology and rehabilitation[J]. Br J Anaesth, 1997, 78(5):606-617. doi: 10.1093/bja/78.5.606 URL
[89]	WU Y, XUE H, ZHANG W, et al. Application of enhanced recovery after surgery in total knee arthroplasty in patients with haemophilia A: A pilot study[J]. Nurs Open, 2020, 8(1):80-86. doi: 10.1002/nop2.v8.1 URL
[90]	王英, 鲍哲恒, 范猛, 等. 血友病性关节炎行全膝置换术患者康复治疗的效果[J]. 实用临床医学, 2019, 20(6):30-33.
	WANG Y, BAO Z H, FAN M, et al. Efficacy of rehabilitation therapy after total knee arthroplasty in patients with hemophilic arthritis[J]. Pract Clin Med, 2019, 20(6):30-33.
[91]	陈岩, 王玥, 王炜. 15例甲型血友病性关节炎全膝关节置换术后康复治疗的临床观察[J]. 中国临床医生杂志, 2018, 46(12):1468-1469.
	CHEN Y, WANG Y, WANG W. Clinical observation on rehabilitation treatment of 15 patients with type A haemophilia arthritis after total knee Joint replacement[J]. Chin J Clin, 2018, 46(12):1468-1469.
[92]	高娜, 佟冰渡, 张燕, 等. 血友病性骨关节病患者关节置换术围术期管理策略的应用效果研究[J]. 中国护理管理, 2019, 19(4):607-611.
	GAO N, TONG B D, ZHANG Y, et al. The effectiveness of perioperative management of patients with hemophiliac osteoarthrosis[J]. Chin Nurs Manag, 2019, 19(4):607-611.
[93]	LIU S, LI K, ZHAO X, et al. Survey of non-physiotherapy department medical staff in China and their understan-ding of physiotherapy in comprehensive management of haemophilia[J]. Haemophilia, 2019, 25(3):493-499. doi: 10.1111/hae.2019.25.issue-3 URL
[94]	SUN J, LI Z, HUANG K, et al. F8 gene mutation spectrum in severe hemophilia A with inhibitors: A large cohort data analysis from a single center in China[J]. Res Pract Thromb Haemost, 2022, 6(4):e12723. doi: 10.1002/rth2.12723 URL
[95]	朱履锴, 张夏林, 刘秀娥, 等. 单中心重型血友病A患者FⅧ基因突变类型与FⅧ抑制物产生的相关性分析[J]. 中国实验血液学杂志, 2022, 30(5):1536-1540.
	ZHU L K, ZHANG X L, LIU X E, et al. Correlation analysis of FⅧ gene mutation and the production of FⅧ inhibitor with severe gemophilia A patients in a single medical center[J]. J Exp Hematol, 2022, 30(5): 1536-1540.
[96]	LIU W, LYU C, WANG W, et al. Risk factors for inhibitors in hemophilia A based on RNA-seq and DNA methylation[J]. Res Pract Thromb Haemost, 2022, 6(6):e12794. doi: 10.1002/rth2.12794 URL
[97]	LU Y, CHEN Z, DAI J, et al. Maternal microchimerism protects hemophilia A patients from inhibitor development[J]. Blood Adv, 2020, 4(9):1867-1869. doi: 10.1182/bloodadvances.2020001832 pmid: 32374877
[98]	DOU X, ZHANG W, POON M C, et al. Factor Ⅸ inhibitors in haemophilia B: a report of national haemophilia registry in China[J]. Haemophilia, 2023, 29(1):123-134. doi: 10.1111/hae.v29.1 URL
[99]	LIU G, SUN J, LI Z, et al. F9 mutations causing deletions beyond the serine protease domain confer higher risk for inhibitor development in hemophilia B[J]. Blood, 2023, 141(6):677-680. doi: 10.1182/blood.2022017871 URL
[100]	商保军, 杨世伟, 雷平冲, 等. 血友病A患儿凝血因子Ⅷ抑制物相关临床研究[J]. 中华血液学杂志, 2020, 41(2):138-142.
	SHANG B J, YANG S W, LEI P C, et al. Clinical study on factor Ⅷ inhibitor in children with hemophilia A[J]. Chin J Hematol, 2020, 41(2):138-142.
[101]	魏琪琪, 唐凌, 陈振萍, 等. 单中心儿童血友病A抑制物累积发生率及危险因素[J]. 中华实用儿科临床杂志, 2017, 32(3):212-215.
	WEI Q Q, TANG L, CHEN Z P, et al. Status and risk factors of inhibitor occurrence in single-center children with hemophilia[J]. Chin J Appl Clin Pediatr, 2017, 32(3):212-215.
[102]	张庆, 杨小兰, 刘晓丽, 等. 儿童血友病A抑制物产生的危险因素分析及随访研究[J]. 血栓与止血学, 2019, 25(1):4-7.
	ZHANG Q, YANG X L, LIU X L, et al. Study on risk factors and follow-up of coagulation factor Ⅷ inhibitor in children with hemophilia A[J]. Chin J Thromb Hemost, 2019, 25(1):4-7.
[103]	张露璐, 余自强, 张威, 等. 血友病A患者产生凝血因子Ⅷ抑制物的相关因素分析[J]. 中华血液学杂志, 2010, 31(3):168-171.
	ZHANG X L, YU Z Q, ZHANG W, et al. Analysis of coa-gulation factor Ⅷ inhibitor development related factors in hemophilia A patients[J]. Chin J Hematol, 2010, 31(3):168-171.
[104]	中华医学会血液学分会血栓与止血学组, 中国血友病协作组. 凝血因子Ⅷ/Ⅸ抑制物诊断与治疗中国指南(2018年版)[J]. 中华血液学杂志, 2018, 39(10):793-799.
	Thrombosis and Hemostasis Group, Chinese Society ofHematology, Chinese Medical Association Hemophilia Treatment Center Collaborative Network of China. Chinese guidelines on the diagnosis and treatment of coagulation factor Ⅷ/Ⅸ inhibitors (version 2018)[J]. Chin J Hematol, 2018, 39(10):793-799.
[105]	DOU X Q, LIU W, POON M C, et al. Patients with haemophilia A with inhibitors in China: a national real-world analysis and follow-up[J]. Br J Haematol, 2021, 192(5): 900-908. doi: 10.1111/bjh.v192.5 URL
[106]	LIU W, XUE F, POON M C, et al. Current status of haemophilia inhibitor management in mainland China: a haemophilia treatment centres survey on treatment prefe-rences and real-world clinical practices[J]. Br J Haematol, 2021, 194(4):750-758. doi: 10.1111/bjh.v194.4 URL
[107]	刘葳, 薛峰, 刘晓帆, 等. 重组人凝血因子Ⅶa治疗血液病患者出血的临床疗效分析[J]. 中华血液学杂志, 2017, 38(5):410-414.
	LIU W, XUE F, LIU X F, et al. Analysis of clinical efficacy of recombinant activated factor Ⅶ on bleeding in patients with hematologic disorders[J]. Chin J Hematol, 2017, 38(5):410-414.
[108]	LIU W, XUE F, FU R, et al. Preclinical studies of a factor X activator and a phase 1 trial for hemophilia patients with inhibitors[J]. J Thromb Haemost, 2023, 21(6):1453-1465. doi: 10.1016/j.jtha.2023.01.040 pmid: 36796484
[109]	张磊, 薛峰, 刘晓帆, 等. 血友病A伴抑制物一例及其免疫耐受诱导治疗探讨[J]. 中华血液学杂志, 2010, 31(9):577-580.
	ZHANG L, XUE F, LIU X F, et al. Immune tolerance induction in a severe hemophilia A patient with inhibitor[J]. Chin J Hematol, 2010, 31(9):577-580.
[110]	LI Z, CHEN Z, CHENG X, et al. Low-dose immune tole-rance induction for children with hemophilia A with poor-risk high-titer inhibitors: A pilot study in China[J]. Res Pract Thromb Haemost, 2019, 3(4):741-748. doi: 10.1002/rth2.12248 URL
[111]	UNUVAR A, KAVAKLI K, BAYTAN B, et al. Low-dose immune tolerance induction for paediatric haemophilia patients with factor Ⅷ inhibitors[J]. Haemophilia, 2008, 14(2):315-322. doi: 10.1111/hae.2008.14.issue-2 URL
[112]	ElAlfy M S, Tantawy A A, Ahmed M H, et al. Frequency of inhibitor development in severe haemophilia A children treated with cryoprecipitate and low-dose immune tolerance induction[J]. Haemophilia, 2000, 6(6):635-638. pmid: 11122388
[113]	DOU X, ZHANG W, POON M C, et al. Factor Ⅸ inhibitors in haemophilia B: A report of National Haemophilia Registry in China[J]. Haemophilia, 2023, 29(1):123-134. doi: 10.1111/hae.v29.1 URL
[114]	薛峰, 刘葳, 陈云飞, 等. 凝血酶原复合物联合小剂量利妥昔单抗治疗血友病B伴抑制物[J]. 中华血液学杂志, 2017, 38(9):749-753.
	XUE F, LIU W, CHEN Y F, et al. Immune tolerance induction in a case of hemophilia B with inhibitor with prothrombin complex concentrate and rituximab[J]. Chin J Hematol, 2017, 38(9):749-753.
[115]	LI Z, LIU G, YAO W, et al. Eradication of FⅨ inhibitor in haemophilia B children using low-dose immune tole-rance induction with rituximab-based immunosuppressive agent(s) in China[J]. Haemophilia, 2022, 28(4):625-632. doi: 10.1111/hae.v28.4 URL
[116]	LI Z, LIU G, YAO W, et al. Nephrotic syndrome in two haemophilia B children with inhibitor under low-dose immune tolerance induction combined with rituximab-based immunosuppressant protocol[J]. Haemophilia, 2022, 28(2):e42-e45.
[117]	李晓姗, 刘希茂, 何小霞. 南方医院完成合并重型血友病伴抑制物形成的体外循环心脏手术[J]. 中华医学信息导报, 2021, 36(19):9.
	LI X S, LIU X M, HE X X. Nanfang Hospital completed cardiopulmonary bypass cardiac surgery with severe Haemophilia and inhibitor formation[J]. China Med News, 2021, 36(19):9.
[118]	徐佩佩, 周虎, 张鹏, 等. 重组活化凝血因子Ⅶ联合凝血酶原复合物在血友病A伴高滴度抑制物患者围手术期的应用[J]. 中华血液学杂志, 2020, 41(9):773-775.
	XU P P, ZHOU H, ZHANG P, et al. Perioperative application of recombinant human coagulation factor Ⅶa combined with prothrombin complex in two hemophilia A patients with high titer inhibitor[J]. Chin J Hematol, 2020, 41(9):773-775.
[119]	李军, 丁小玲, 吕冰梅, 等. 血友病性膝关节病的超声特征[J]. 中华血液学杂志, 2014, 35(5):434-437.
	LI J, DING X L, LV B M, et al. Ultrasonographic characteristics of haemophilic arthropathy in the knee joints[J]. Chin J Hematol, 2014, 35(5):434-437.
[120]	李军, 郭新娟, 丁小玲, 等. 血友病性关节病HEAD-US半定量超声评估量表的临床应用及优化探索[J]. 中华血液学杂志, 2018, 39(2):132-136.
	LI J, GUO X J, DING X L, et al. Clinical application and optimization of HEAD-US quantitative ultrasound assessment scale for hemophilic arthropathy[J]. Chin J Hematol, 2018, 39(2):132-136.
[121]	李军, 刘葳, 郭新娟, 等. HEAD-US-C超声评估量表对中间型/重型血友病A患者按需和预防替代治疗关节损伤评价[J]. 中华血液学杂志, 2018, 39(10):817-821.
	LI J, LIU W, GUO X J, et al. HEAD-US-C quantitative ultrasound assessment scale in evaluation of joint damage in patients with moderate or severe hemophilia A received on-demand versus prophylaxis replacement therapy[J]. Chin J Hematol, 2018, 39(10):817-821.
[122]	方云梅, 郭玉林, 秦婷, 等. 血友病性关节超声评估量表评分与其临床功能评分的相关性研究[J]. 临床超声医学杂志, 2020, 22(7):510-514.
	FANG Y M, GUO Y L, QIN T, et al. Correlation between ultrasonic evaluation score and clinical function score in hemophiliac arthropathy[J]. J Clin Ultrasound Med, 2020, 22(7):510-514.
[123]	ZHAO L, YANG H, LI Y, et al. Joint status and related risk factors in patients with severe hemophilia A: a single-center cross-sectional study[J]. Hematology, 2022, 27(1): 80-87. doi: 10.1080/16078454.2021.2019892 pmid: 34964431
[124]	中国血友病协作组. 血友病性关节病超声评估专家共识(2022年版)[J]. 中华医学超声杂志(电子版), 2022, 19(9):877-881.
	Hemophilia Treatment Center Collaborative Network of China. Expert consensus on ultrasonic diagnosis and scoring of hemophiliac arthropathy (2022 edition)[J]. Chin J Med Ultrasound (El Ed), 2022, 19(9):877-881.
[125]	ZHANG C M, ZHANG J F, XU J, et al. Musculoskeletal ultrasonography for arthropathy assessment in patients with hemophilia: A single-center cross-sectional study from Shanxi Province, China[J]. Medicine (Baltimore), 2018, 97(46):e13230. doi: 10.1097/MD.0000000000013230 URL
[126]	WU R, ZHANG J, LUKE K H, et al. Cross-cultural adaptation of the CHO-KLAT for boys with hemophilia in rural and urban China[J]. Health Qual Life Outcomes, 2012, 10:112. doi: 10.1186/1477-7525-10-112
[127]	WU R, ZHANG J, SUN J, et al. Validation of the Chinese version of the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool (the CHO-KLAT)[J]. Haemophilia, 2014, 20(6):794-799. doi: 10.1111/hae.12489 pmid: 25273150
[128]	TANG L, XU W, LI C G, et al. Describing the quality of life of boys with haemophilia in China: Results of a multicentre study using the CHO-KLAT[J]. Haemophilia, 2018, 24(1):113-119. doi: 10.1111/hae.13349 pmid: 28922525
[129]	ZHANG H, HUANG J, KONG X, et al. Health-related quality of life in children with haemophilia in China: a 4-year follow-up prospective cohort study[J]. Health Qual Life Outcomes, 2019, 17(1):28. doi: 10.1186/s12955-019-1083-3
[130]	ZHANG W, XIE S, XUE F, et al. Health-related quality of life among adults with haemophilia in China: A comparison with age-matched general population[J]. Haemophilia, 2022, 28(5):776-783. doi: 10.1111/hae.v28.5 URL
[131]	马乐, 范猛, 薛峰, 等. 按需治疗血友病患者关节健康状况临床分析[J]. 中国实验血液学杂志, 2019, 27(1): 185-191.
	MA L, FAN M, XUE F, et al. Cinical analysis of joint health status of patients with hemophilia treated on demand[J]. J Exp Hematol, 2019, 27(1):185-191.
[132]	WU W, ZHOU X, JIANG Z, et al. Noninvasive fetal genotyping of single nucleotide variants and linkage analysis for prenatal diagnosis of monogenic disorders[J]. Hum Genomics, 2022, 16(1):28. doi: 10.1186/s40246-022-00400-4 pmid: 35897115
[133]	CHEN C, SUN J, YANG Y, et al. Noninvasive prenatal diagnosis of hemophilia A by a haplotype-based approach using cell-free fetal DNA[J]. Biotechniques, 2020, 68(3):117-121. doi: 10.2144/btn-2019-0113 pmid: 31996009
[134]	DAI J, LU Y, DING Q, et al. The status of carrier and prenatal diagnosis of haemophilia in China[J]. Haemophilia, 2012, 18(2):235-240. doi: 10.1111/j.1365-2516.2011.02630.x pmid: 21910785
[135]	FENG Y, LI Q, SHI P, et al. Mutation analysis in the F8 gene in 485 families with haemophilia A and prenatal diagnosis in China[J]. Haemophilia, 2021, 27(1):e88-e92.
[136]	CHEN J, WANG J, LIN X Y, et al. Genetic diagnosis in Hemophilia A from southern China: five novel mutations and one preimplantation genetic analysis[J]. Int J Lab Hematol, 2017, 39(2):191-201. doi: 10.1111/ijlh.12602 pmid: 27868395
[137]	HUANG Z, NICHOLAS S, YANG Y, et al. Medical costs and hospital utilization for hemophilia A and B urban inpatients in China: a national cross-sectional study[J]. BMC Health Serv Res, 2022, 22(1):230. doi: 10.1186/s12913-022-07626-x pmid: 35183186
[138]	王旭, 贺小宁, 吴晶. 我国基本医疗保险报销政策对成人血友病A患者治疗水平与费用的影响[J]. 中华医院管理杂志, 2020, 36(6):485-489.
	WANG X, HE X N, WU J. Effect of reimbursement policy of basic medical insurance on the treatment level and cost of hemophilia A patients in China[J]. Chin J Hosp Adm, 2020, 36(6):485-489.
[139]	QU C, LIU W, CHEN L, et al. Analysis of hospitalization of people with hemophilia-12 years of experience in a single center[J]. Res Pract Thromb Haemost, 2022, 6(5):e12764. doi: 10.1002/rth2.12764 URL

预防治疗强度	血友病A	血友病B
高剂量预防	25~40 IU/kg，隔日1次 [>4 000 IU/（kg·年）]	40~60 IU/kg，每周2次 [>4 000 IU/（kg·年）]
中剂量预防	15~25 IU/kg，每周3次（每年1 500~4 000 IU/kg）	20~40 IU/kg，每周2次（每年2 000~4 000 IU/kg）
低剂量预防	10~15 IU/kg，每周2~3次（每年1 000~1 500 IU/kg）	10~15 IU/kg，每周2次（每年1 000~1 500 IU/kg）